Literature DB >> 7840593

Efficacies of different vancomycin dosing regimens against Staphylococcus aureus determined with a dynamic in vitro model.

S B Duffull1, E J Begg, S T Chambers, M L Barclay.   

Abstract

A dynamic in vitro model was used to assess four different vancomycin dosing regimens against Staphylococcus aureus. These regimens achieved peak drug concentrations of 48 micrograms/ml (single dose) and 30 micrograms/ml (dosed every 12 h) and constant concentrations of 16 and 8 micrograms/ml. Analysis of the area under the bacterial concentration-time curve, area under the first moment of the bacterial concentration-time curve, and bacterial elimination rate constant showed no difference in the rate or extent of bacterial killing. The optimal dosing method may be that which achieves the lowest area under the curve while concentrations are maintained above the MBC.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7840593      PMCID: PMC284768          DOI: 10.1128/AAC.38.10.2480

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  19 in total

1.  Antibiotic therapy of bacterial endocarditis. VII. Vancomycin for acute micrococcal endocarditis; preliminary report.

Authors:  J E GERACI; F R HEILMAN; D R NICHOLS; W E WELLMAN
Journal:  Proc Staff Meet Mayo Clin       Date:  1958-04-02

2.  Vancomycin.

Authors:  J E Geraci
Journal:  Mayo Clin Proc       Date:  1977-10       Impact factor: 7.616

3.  Time-kill studies with oxacillin, vancomycin, and teicoplanin versus Staphylococcus aureus.

Authors:  R N Greenberg; C A Benes
Journal:  J Infect Dis       Date:  1990-05       Impact factor: 5.226

4.  Survey of vancomycin monitoring guidelines in Illinois hospitals.

Authors:  W E Fitzsimmons; M J Postelnick; P V Tortorice
Journal:  Drug Intell Clin Pharm       Date:  1988 Jul-Aug

5.  Vancomycin serum levels and toxicity in chronic hemodialysis patients with Staphylococcus aureus bacteremia.

Authors:  H Masur; P Francioli; M Ruddy; H W Murray
Journal:  Clin Nephrol       Date:  1983-08       Impact factor: 0.975

6.  Vancomycin therapy for methicillin-resistant Staphylococcus aureus.

Authors:  T C Sorrell; D R Packham; S Shanker; M Foldes; R Munro
Journal:  Ann Intern Med       Date:  1982-09       Impact factor: 25.391

7.  Bactericidal activity and killing rate of serum in volunteers receiving ciprofloxacin alone or in combination with vancomycin.

Authors:  P Van der Auwera; J Klastersky
Journal:  Antimicrob Agents Chemother       Date:  1986-12       Impact factor: 5.191

8.  Antimicrobial effects of lomefloxacin in vitro.

Authors:  S T Chambers; B A Peddie; R A Robson; E J Begg; D R Boswell
Journal:  J Antimicrob Chemother       Date:  1991-04       Impact factor: 5.790

9.  Bactericidal activity and killing rate of serum in volunteers receiving vancomycin or teicoplanin with and without amikacin given intravenously.

Authors:  P Van der Auwera; J Klastersky
Journal:  J Antimicrob Chemother       Date:  1987-05       Impact factor: 5.790

10.  How vancomycin is used in Australasia--a survey.

Authors:  S B Duffull; S T Chambers; E J Begg
Journal:  Aust N Z J Med       Date:  1993-12
View more
  10 in total

1.  Use of Modeling Techniques to Aid in Antibiotic Selection.

Authors:  Alexander A. Firsov; Stephen H. Zinner
Journal:  Curr Infect Dis Rep       Date:  2001-02       Impact factor: 3.725

2.  Parameters of bacterial killing and regrowth kinetics and antimicrobial effect examined in terms of area under the concentration-time curve relationships: action of ciprofloxacin against Escherichia coli in an in vitro dynamic model.

Authors:  A A Firsov; S N Vostrov; A A Shevchenko; G Cornaglia
Journal:  Antimicrob Agents Chemother       Date:  1997-06       Impact factor: 5.191

3.  Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model.

Authors:  J D Knudsen; K Fuursted; F Espersen; N Frimodt-Møller
Journal:  Antimicrob Agents Chemother       Date:  1997-09       Impact factor: 5.191

4.  Cerebrospinal fluid penetration and pharmacokinetics of vancomycin administered by continuous infusion to mechanically ventilated patients in an intensive care unit.

Authors:  J Albanèse; M Léone; B Bruguerolle; M L Ayem; B Lacarelle; C Martin
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

Review 5.  Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis.

Authors:  Jason A Roberts; Jeffrey Lipman
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Continuous versus intermittent infusion of vancomycin in severe Staphylococcal infections: prospective multicenter randomized study.

Authors:  M Wysocki; F Delatour; F Faurisson; A Rauss; Y Pean; B Misset; F Thomas; J F Timsit; T Similowski; H Mentec; L Mier; D Dreyfuss
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

7.  In vivo pharmacodynamic activity of the glycopeptide dalbavancin.

Authors:  David Andes; William A Craig
Journal:  Antimicrob Agents Chemother       Date:  2007-02-16       Impact factor: 5.191

8.  Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation.

Authors:  Hussain Mulla; Suneel Pooboni
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

Review 9.  Selecting antibacterials for outpatient parenteral antimicrobial therapy : pharmacokinetic-pharmacodynamic considerations.

Authors:  Richard S Slavik; Peter J Jewesson
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

10.  In vitro studies of pharmacodynamic properties of vancomycin against Staphylococcus aureus and Staphylococcus epidermidis.

Authors:  E Löwdin; I Odenholt; O Cars
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.